IceCure Medical Ltd. — SEC Form D Filing
IceCure Medical Ltd. filed an SEC Form D on June 25, 2026, reporting $16.50M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- June 25, 2026
- Amount reported
- $16.50M
- Round stage
- Series B+
- Industry
- Medical Devices
- Website
- https://www.icecure-medical.com/
What the company does
Revenue: $1,000,001 - $5,000,000. Exemption: Rule 506(b). Incorporated: ISRAEL
Problem
Current treatments for breast cancer, such as surgery, often involve tissue removal, general anesthesia, and lengthy hospital stays, which can be daunting and invasive for patients.
Solution
IceCure Medical offers cryoablation using its ProSense® Cryoablation System, a minimally invasive treatment that freezes and destroys tumors without surgery, general anesthesia, or long hospital stays.
Why now
Advances in medical technology and increasing patient demand for less invasive treatment alternatives are driving the adoption of procedures like cryoablation.
Verdict
Investors funded this because it presented a clear alternative to a well-understood, high-cost procedure, not because it promised a novel therapeutic mechanism. The implicit bet was on a clear, direct cost-saving and patient experience improvement for a specific patient segment. This limited upside to adoption rates within existing clinical practice rather than market expansion, as the solution primarily optimizes an existing treatment path rather than creating a new one.
Source: SEC EDGAR Form D filing